Atlas Trials

Fundación GECP

25 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Fundación GECP

RecordFirmDate
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) (NCT07247786)Fundación GECP2026-09-15
PALACE: Cemiplimab Trial According to ctDNA Levels (NCT06917573)Fundación GECP2025-07-29
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) (NCT07153445)Fundación GECP2025-07-08
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (NCT06431633)Fundación GECP2025-02-04
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients (NCT06634199)Fundación GECP2024-10-03
Characteristics of Sexual Dysfunction in Patients With Lung Cancer (NCT06018376)Fundación GECP2023-07-13
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors (NCT05684276)Fundación GECP2023-05-12
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (NCT05384015)Fundación GECP2022-11-07
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment (NCT05382052)Fundación GECP2022-06-17
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (NCT05398094)Fundación GECP2022-03-21
Pathological Response After Neoadjuvant Treatment on NSCLC (NCT05167487)Fundación GECP2021-12-13
Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment (NCT05167500)Fundación GECP2021-12-09
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NCT05012254)Fundación GECP2021-11-18
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (NCT05005429)Fundación GECP2021-09-20
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (NCT04776447)Fundación GECP2021-06-16
Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients (NCT05009030)Fundación GECP2021-05-06
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NCT04564157)Fundación GECP2021-01-13
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients (NCT04512430)Fundación GECP2020-12-02
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. (NCT04285866)Fundación GECP2020-05-21
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (NCT04223596)Fundación GECP2020-05-04
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection (NCT04407143)Fundación GECP2020-04-15
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (NCT03836066)Fundación GECP2019-05-15
NADIM II: Neo-Adjuvant Immunotherapy (NCT03838159)Fundación GECP2019-05-15
Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive (NCT03790397)Fundación GECP2019-02-26

Track Fundación GECP automatically

Every clearance here is in the API, with alerts when new ones post.